17. Use of the antibody set forth in any one of claims 1, 2, 4, 5, and 6, or the Fab set forth in any one of claims 1, 3, 7, 8 and 9, or the antigen-binding fragment set forth in claim 10, or the gene set forth in any one of claims 11-14, or the genetic material set forth in claim 15 or 16 for:

d1) preparation of a medication for preventing and/or treating diseases associated with human tumor necrosis factor-α, or

d2) preparation of a product for neutralizing the human tumor necrosis factor-α, or

d3) preparation of a kit for qualitatively or quantitatively detecting the human tumor necrosis factor-α.

18. A pharmaceutical composition, comprising auxiliary materials and active ingredients, wherein the active ingredients include at least one of the following materials: the antibody set forth in any one of claims 1, 2, 4, 5, and 6, the Fab set forth in any one of claims 1, 3, 7, 8 and 9, the antigen-binding fragment set forth in claim 10, the gene set forth in any one of claims 11-14, and the genetic material set forth in claim 15 or 16; and the auxiliary material is a pharmaceutically acceptable carrier or excipient.

~~19. Use of any one of the following materials in the treatment of diseases associated with human tumor necrosis factor-α: the antibody set forth in any one of claims 1, 2, 4, 5, and 6, the Fab set forth in any one of claims 1, 3, 7, 8 and 9, the antigen-binding fragment set forth in claim 10, the gene set forth in any one of claims 11-14, and the genetic material set forth in claim 15 or 16, and the pharmaceutical composition set forth in claim 18.~~

19~~20~~. The use of claim 17~~ or claim 19~~, characterized in that the said disease associated with human tumor necrosis factor-α is a disease caused by increase of human tumor necrosis factor-α, preferably rheumatoid arthritis, autoimmune uveitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, or juvenile idiopathic arthritis.